Gossamer Bio, Inc. (GOSS) stock
GOSSNasdaqPharmaceutical PreparationsFiscal year ends December 31
$11.43+0.39 (+3.53%)
Close on Nov 18, 2026Market cap $5.59BP/E –Yield –
Gossamer Bio operating income
Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.
Gossamer Bio's operating income for the twelve months ending Jun 30, 2026 was -$166.09M. For fiscal 2025 it was -$170.73M. The highest annual figure on record is -$6.65M in fiscal 2017.
Annual operating income
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$170.73M | – |
| FY2024 | Dec 31, 2024 | -$59.92M | – |
| FY2023 | Dec 31, 2023 | -$183.76M | – |
| FY2022 | Dec 31, 2022 | -$218.59M | – |
| FY2021 | Dec 31, 2021 | -$216.12M | – |
| FY2020 | Dec 31, 2020 | -$233.96M | – |
| FY2019 | Dec 31, 2019 | -$186.14M | – |
| FY2018 | Dec 31, 2018 | -$148.99M | – |
| FY2017 | Dec 31, 2017 | -$6.65M | – |
Quarterly operating income
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | -$26.07M | – |
| Q1 FY2026 | Mar 31, 2026 | -$44.87M | – |
| Q4 FY2025 | Dec 31, 2025 | -$46.04M | – |
| Q3 FY2025 | Sep 30, 2025 | -$49.11M | – |
| Q2 FY2025 | Jun 30, 2025 | -$38.77M | -174.4% |
| Q1 FY2025 | Mar 31, 2025 | -$36.81M | – |
| Q4 FY2024 | Dec 31, 2024 | -$36.13M | – |
| Q3 FY2024 | Sep 30, 2024 | -$33.92M | – |
| Q2 FY2024 | Jun 30, 2024 | $52.09M | – |
| Q1 FY2024 | Mar 31, 2024 | -$41.96M | – |
| Q4 FY2023 | Dec 31, 2023 | -$49.03M | – |
| Q3 FY2023 | Sep 30, 2023 | -$40.49M | – |
| Q2 FY2023 | Jun 30, 2023 | -$46.30M | – |
| Q1 FY2023 | Mar 31, 2023 | -$47.94M | – |
| Q4 FY2022 | Dec 31, 2022 | -$54.36M | – |
| Q3 FY2022 | Sep 30, 2022 | -$56.02M | – |
| Q2 FY2022 | Jun 30, 2022 | -$53.87M | – |
| Q1 FY2022 | Mar 31, 2022 | -$54.34M | – |
| Q4 FY2021 | Dec 31, 2021 | -$51.66M | – |
| Q3 FY2021 | Sep 30, 2021 | -$55.66M | – |
| Q2 FY2021 | Jun 30, 2021 | -$55.60M | – |
| Q1 FY2021 | Mar 31, 2021 | -$53.20M | – |
| Q4 FY2020 | Dec 31, 2020 | -$60.09M | – |
| Q3 FY2020 | Sep 30, 2020 | -$53.57M | – |
| Q2 FY2020 | Jun 30, 2020 | -$65.34M | – |
| Q1 FY2020 | Mar 31, 2020 | -$54.97M | – |
| Q4 FY2019 | Dec 31, 2019 | -$55.79M | – |
| Q3 FY2019 | Sep 30, 2019 | -$49.99M | – |
| Q2 FY2019 | Jun 30, 2019 | -$46.35M | – |
| Q1 FY2019 | Mar 31, 2019 | -$34.02M | – |
| Q4 FY2018 | Dec 31, 2018 | -$39.81M | – |
| Q3 FY2018 | Sep 30, 2018 | -$50.02M | – |
| Q2 FY2018 | Jun 30, 2018 | -$33.04M | – |
| Q1 FY2018 | Mar 31, 2018 | -$26.13M | – |
See a number that looks wrong?